Supplementary Table 1. Inclusion and exclusion criteria

Inclusion criteria
Patients aged ≥18 years
Patients with type 2 diabetes
Patients hospitalized for an expected length of at least 5 days (maximum of 2 weeks)
hemodynamically stable
Patients treated with basal insulin and/or non-insulin antidiabetic drugs before hospital admission
Patients poorly controlled (HbA1c levels 8-10%) at hospital admission, after at least 3 months of unchanged antidiabetic therapy
Patients who sign informed consent to participate in the study
Exclusion criteria
Patients with type 1 diabetes
Patients hospitalized due to hyperglycaemic decompensation of diabetes
Patients with a psychiatric or neurological disability that prevents their follow-up
Patients whose health or cognitive status does not allow them to perform a correct titration or administration of insulin
Patients critically ill
Patients treated with premixed insulin or rapid-acting insulin (basal-plus or basal-bolus, except for the treatment of gestational diabetes or short treatment with insulin for less than 1 week). Patients may have received treatment with premixed or rapid-acting insulin in a timely manner as a corrective treatment during admission before inclusion in the clinical trial, provided it was of a duration of less than 7 days
Patients with glomerular filtration rate (GFR) <30 ml/minute according to the Modification of Diet in Renal Disease-4 (MDRD-4) equation
Very high-risk patients who will need mandatory treatment with rapid-acting insulin at discharge (oral or parenteral corticosteroid treatment or pancreatic insufficiency due to pancreatitis or surgery)
Patients who are participating in another study

Patients requiring treatment intensification with rapid-acting insulin at discharge

Pregnant or lactating women

Women of childbearing age who do not use contraception during the study

Patients unable to give informed consent insulin at hospital discharge